Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, is described. The methods can be used to reduce the severity of outcomes related to COVID-19, such as hospitalization and ventilation. For example, treatment of a subject with a therapeutic agent that neutralizes interleukin 13 (IL-13) can result in reduced risk for mechanical ventilation in the subject. Also described are methods of predicting risk of mechanical ventilation in subjects with COVID-19.

Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.

A method for the identification of compounds modulating the biological activity of FGF2, the method comprising the use of target cells sensitive to the presence of FGF2 by obstructing proliferation, wherein the target cells constitutively express a first reporter in the nucleus of living target cells.

The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.

Disclosed herein are methods, kits, tests, and systems for detecting, predicting, monitoring, or ruling out preeclampsia in pregnant women. Also provided herein are novel diagnostic markers, methods of data analysis, assay formats, and kits employing such markers to improve one or more characteristics of a test for identifying or ruling out preeclampsia based on biomarkers from patient samples.

The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.

The present invention provides a novel use of fibroblast growth factor 2 (FGF-2), i.e., a use of FGF-2 in preparation of medicine. The uses of the medicine are the following (a) and/or (b) and/or (c): (a) the prevention and/or treatment of lung injury; (b) the prevention and/or treatment of influenza; (c) the prevention and/or treatment of diseases caused by influenza viruses.

A method for increasing the veracity of classification by detecting protein YKL-40 and MASP2 levels in the samples, comprises detecting the content of the YKL-40 and MASP2 in the samples; the ratio of the content of YKL-40 to the that of MASP2 acted as variable, receiving the ROC curve according to the sensitivity and specialty of the difference threshold value to the diagnosis for the cancer, calculating an area under the curve AUC; classifying the samples according to the value of the AUC, sensitivity and specialty. And a kit for detecting the protein YKL-40 and MASP2 levels in the samples.

Methods of using biomarkers in determining the efficacy of a treatment for an organic acidemia in a subject are disclosed herein. Methods of using biomarkers in determining the efficacy of a liver-directed treatment for an organic acidemia in a subject are likewise disclosed herein.

The present invention relates, in one aspect, to certain mutant FGF21 polypeptide constructs. In certain non-limiting embodiments, the construct binds to β-Klotho more tightly than wild-type FGF21. In certain non-limiting embodiments, the construct has a mutation in at least one residue of SEQ ID NO:3 selected from the group consisting of V188, R203, and L194. In certain non-limiting embodiments, the construct further comprises a stability enhancing domain.